12 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 12 of 12 clinical reviews.
Specific dietary, meal-timing, hydration, and lifestyle strategies with clinical evidence for reducing progesterone-induced sedation from allopregnanolone GABA-A activity.
A clinical deep-dive into OTC and prescription options for managing progesterone-induced sedation, including dose ranges, timing strategies, drug interactions to avoid, and when to escalate or switch formulations.
Learn why oral micronized progesterone causes sedation through its allopregnanolone metabolite, how to manage drowsiness, and when sedation signals a need for medical attention.
Why sedation from oral micronized progesterone persists in some patients, what drives it biochemically, and evidence-based strategies to manage or eliminate it.
Why oral micronized progesterone causes sedation through its allopregnanolone metabolite, how to manage drowsiness, and which progesterone formulations avoid GABA-A receptor activity.
A clinical severity grading rubric for sedation caused by oral micronized progesterone (Prometrium), including mechanism, management strategies, and when to adjust therapy.
Why oral micronized progesterone causes sedation, how long it lasts, and which supplements have the strongest clinical evidence for managing drowsiness without abandoning therapy.
How common is sedation on oral micronized progesterone, how severe does it get, who is most at risk, and what does the evidence say about how it resolves? A clinically detailed overview for patients and prescribers.
A week-by-week clinical breakdown of progesterone-related sedation: when it starts, when it peaks, when it resolves, and what the trial data show. Includes dosing strategies, red flags, and patient FAQs.
Precise clinical criteria for when sedation from oral micronized progesterone crosses the threshold for discontinuation, including severity grading, quality-of-life benchmarks, alternative regimens, and what the trial evidence actually says.
Oral micronized progesterone causes sedation because the liver converts a portion of the dose to allopregnanolone, a neurosteroid that modulates GABA-A receptors. This explains the mechanism, the dose and route dependence, and how clinicians manage the effect.
A clinical deep-dive into why oral micronized progesterone causes sedation, covering the allopregnanolone-GABA-A receptor mechanism, dose-response data, and practical strategies to manage drowsiness while staying on therapy.